A Phase II Study of Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix
- list item one, to evaluate toxicities of Belotecan
- list item two, to evaluate duration of primary response for responding patients
- list item three, to evaluate time to disease progression
- list item four, to evaluate progression free survival and overall survival.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
overall response rate of belotecan (CKD-602)
1 week before the start of Cycle 4, 3 weeks later Cycle 6 or at discontinuation of study treatment, and then at least every 3 months
Yes
Sokbom Kang
Principal Investigator
National cancer cencer
Korea: Food and Drug Administration
NCCCTS-06-214
NCT00430144
January 2007
October 2010
Name | Location |
---|